From the AGA Journals
From the AGA Journals
Who’s at risk for enterocolitis in Hirschsprung’s?
If these findings identify a predictive marker, it could lead to prophylactic therapy for this often life-threatening complication.
News
AGA Clinical Practice Update: Early complications after bariatric/metabolic surgery
The seven advice statements range from a call for high familiarity with interventions to specific approaches for managing postoperative leaks.
From the AGA Journals
Women in GI: Career-spanning strategies to overcome gender bias
Inherent gender bias – both systemic and self-directed – can bar women from advancing as early as medical school and continue throughout their...
From the Journals
AGA Clinical Practice Update: Chemoprevention for colorectal neoplasia
The update encouraged only a few options for consideration based on effectiveness, affordability, and safety.
From the Journals
AGA Clinical Practice Guidelines: Medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease
These guidelines reflect nearly the improvement in outcomes for Crohn’s disease over recent years, as well as ways forward.
From the AGA Journals
Size, location may help reveal SMICs
These factors may predict which granularly mixed laterally spreading colorectal tumors should be treated by en bloc resection.
From the AGA Journals
Novel oncogene found in hepatoblastoma
NFE2L2 mutations accelerate growth and make this cancer even deadlier.
From the AGA Journals
Thermal ablation may reduce residual, recurrent adenomas
The U.S. Multi-Society Task Force currently recommends EMR-T for large nonpedunculated colorectal polyps, but real-world effectiveness remains...
From the AGA Journals
Low-fat diet upped quality of life in ulcerative colitis
These data suggest that even patients in remission could benefit from a healthier diet, and just as importantly, neither diet exacerbated symptoms...
From the AGA Journals
IL-6 trans-signaling targeted by olamkicept in IBD
Blocking the IL-6/ILR receptor can cause “profound immunosuppression,” but olamkicept “exclusively blocks” IL-6 proinflammatory trans-signaling,...